Genmab — Juni 2016
-
premarket 1285
-
Den seneste jeg har er fra 21.3. Her skrev de - Genmab (Neutral): Lowering 12m TP to DKr950 (from DKr1000)
Post FY15 results, we adjust our 2016 forecasts for sales, R&D, royalty rates and costs. Next catalyst: Potential interim read out from POLLUX and CASTOR studies for daratumumab in second line multiple myeloma in 1H16, which we expect to be positive and to lead to filing in 2H16. -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
det er vi ikke noget vi kan huske...